Stability-indicating UPLC method for quantification of alpelisib in bulk and tablet formulation by QbD approach

被引:0
作者
Majumder, Tandrima [1 ]
Gubbiyappa, Shiva Kumar [2 ]
Iriventi, Padmini [3 ]
机构
[1] COER Univ, Coll Pharm, Roorkee 247667, India
[2] GITAM Deemed Be Univ, Sch Pharm, Medak 502329, Telangana, India
[3] MRM Coll Pharm, Dept Pharmaceut, Ibrahimpatnam 501510, Telangana, India
关键词
ICH guidelines; Alpelisib; QbD; Stability studies; UPLC;
D O I
10.1186/s43094-025-00802-w
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundIn the present study, a new and sensitive UPLC method for stability-indicating study has been established and validated as per the ICH guidelines. To date, no work has been reported on the forced degradation studies of alpelisib using the UPLC technique. Box-Behnken design was used to study the response surface for method optimisation to achieve a good separation with a minimum number of experimental trials. Three independent parameters selected were mobile phase ratio, flow rate of the mobile phase and temperature of the column. Retention time and tailing factor were taken as two responses to obtain mathematical models.ResultsThe chromatography was executed using Waters BEH C18 UPLC column (2.1 x 50 mm, 1.7micron) at wavelength detection of 246 nm. The optimised assay conditions predicted were isocratic mobile solvent system using 0.1% formic acid buffer solution and acetonitrile in the ratio of 50:50 (V/V), with a flow rate of 0.25 mL per min and injection volume of 4 mu L. The method has shown a good response with a total run time of 4 min, retention time was found to be 1.49 min and tailing factor was 0.99 for alpelisib, showing good peak symmetry. The linearity of the method developed is at a range of 10-50 mu g/mL with R2 0.9955, while the percentage mean recovery for accuracy was of 99.25%. The method developed was precise as % RSD of inter-day and intra-day precision was 0.3 and 0.1, respectively, meeting the specified limits.ConclusionThe developed UPLC work is quick and simple with an increased level of linearity, precision, specificity and accuracy as per the ICH criteria and can find application in industries as a regular method for quantification of alpelisib.
引用
收藏
页数:15
相关论文
共 17 条
[1]  
[Anonymous], 2005, Validation of analytical procedures: Text and methodology Q2 (R1)
[2]  
[Anonymous], ICH Q8 (R2) Pharmaceutical Development | European Medicines Agency Available online
[3]   Development and validation of stability indicating UPLC method for the simultaneous estimation of triamterene and hydrochlorothiazide in combined dosage forms using quality by design approach [J].
Devi, D. Akila ;
Bhavani, P. Geetha .
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 9 (01)
[4]  
FDA Approved Drug Products, VIJOICE (alpelisib) tablets
[5]   Development of stability-indicating assay method and liquid chromatography-quadrupole-time-of-flight mass spectrometry-based structural characterization of the forced degradation products of alpelisib [J].
Ghanghav, Vidya ;
Chawathe, Ashwini ;
Chauthe, Siddheshwar Kisan ;
Sharma, Nitish .
BIOMEDICAL CHROMATOGRAPHY, 2024, 38 (03)
[6]  
ICH Harmonized Tripartite, 2003, INT C HARM
[7]  
ICH: Q2B, 1996, P INT C HARM
[8]   Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers [J].
James, Alexander ;
Blumenstein, Lars ;
Glaenzel, Ulrike ;
Jin, Yi ;
Demailly, Arnold ;
Jakab, Annamaria ;
Hansen, Regine ;
Hazell, Katharine ;
Mehta, Anuradha ;
Trandafir, Lucia ;
Swart, Piet .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) :751-760
[9]   Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial [J].
Konstantinopoulos, Panagiotis A. ;
Barry, William T. ;
Birrer, Michael ;
Westin, Shannon N. ;
Cadoo, Karen A. ;
Shapiro, Geoffrey, I ;
Mayer, Erica L. ;
O'Cearbhaill, Roisin E. ;
Coleman, Robert L. ;
Kochupurakkal, Bose ;
Whalen, Christin ;
Curtis, Jennifer ;
Farooq, Sarah ;
Luo, Weixiu ;
Eismann, Julia ;
Buss, Mary K. ;
Aghajanian, Carol ;
Mills, Gordon B. ;
Palakurthi, Sangeetha ;
Kirschmeier, Paul ;
Liu, Joyce ;
Cantley, Lewis C. ;
Kaufmann, Scott H. ;
Swisher, Elizabeth M. ;
D'Andrea, Alan D. ;
Winer, Eric ;
Wulf, Gerburg M. ;
Matulonis, Ursula A. .
LANCET ONCOLOGY, 2019, 20 (04) :570-580
[10]  
Kumari N, 2019, Journal of Drug Delivery and Therapeutics, V9, P1006, DOI [10.22270/jddt.v9i3-s.3114, 10.22270/jddt.v9i3-s.3114, DOI 10.22270/JDDT.V9I3-S.3114]